Considerations on the medication cycle and discontinuation timing of venetoclax/venetoclax

Venetoclax, as a highly effective B-cell lymphoma 2 (BCL-2) inhibitor, has been officially approved by the U.S. Food and Drug Administration (FDA), especially for patients with 17p deletion chronic lymphocytic leukemia (CLL) who have undergone at least one previous treatment. Veneclatshows broad therapeutic potential against a variety of hematological malignancies driven byBCL-2 overexpression, such as acute myeloid leukemia (AML).

When considering the appropriate duration of venetoclax and when it is most appropriate to stop taking it, variables such as the patient's specific condition, response to treatment, overall health, and doctor's advice will have a profound impact on the decision. In clinical studies, in patients in a fasting state, the concentration of venetoclax in the plasma will reach a peak within approximately 5 to 8 hours after taking the drug. When the drug is ingested with food, exposure increases by 3 to 5 times.

For patients with CLL and AML, the terminal elimination half-life of the drug usually remains between 1 and 2 hours. The treatment process is often a journey that takes time and patience. In order to see significant therapeutic effects, patients usually need to continue taking venetoclax for a period of time. During this process, doctors will conduct regular assessments based on the patient's specific situation and treatment progress, and make corresponding adjustments to the treatment plan accordingly.

Once the patient's condition is effectively controlled and the overall health is stable, doctors may consider gradually reducing the dose of the drug and eventually discontinuing it. However, if the patient's condition remains unstable or there is a risk of recurrence, the doctor may recommend continuing the medication or making necessary adjustments to the treatment plan.